Overview

* Procept Biorobotics ( PRCT ) Q3 revenue grows 43% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats consensus, showing improved operational performance

* Company maintains fiscal yr 2025 revenue guidance, issues optimistic 2026 forecast

Outlook

* Company maintains 2025 revenue guidance at $325.5 mln, up 45% from 2024

* Company projects 2026 revenue between $410 mln and $430 mln, up 26%-32% from 2025

* Company expects $2 mln gross margin headwind in Q4 2025 due to tariffs

Result Drivers

* SYSTEM SALES - Increased U.S. system sales to new hospital customers drove revenue growth

* CONSUMABLES REVENUE - U.S. handpiece and consumables revenue rose 50% yr/yr, contributing significantly to total revenue

* GROSS MARGIN IMPROVEMENT - Improved operational efficiencies led to gross margin expansion to 65%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $83.32 $80.94

Revenue mln mln (12

Analysts

)

Q3 Net -$21.41

Income mln

Q3 Beat -$7.39 -$10.19

Adjusted mln mln (7

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Procept Biorobotics Corp ( PRCT ) is $62.00, about 44.3% above its November 3 closing price of $34.51

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)